Quick Overview
- Johnson & Johnson received FDA clearance for Icotyde, a plaque psoriasis pill created with Protagonist Therapeutics (PTGX), triggering a ~4.69% decline in ABBV shares
- The once-daily oral medication positions itself as a competitor to AbbVie’s leading immunology asset, Skyrizi
- Wall Street analysts maintain expectations for Skyrizi sales to expand 23% through FY2026
- ABBV shares are trading beneath the SMA-20 ($227.73), SMA-50 ($224.27), and marginally below the SMA-200 ($214.95), indicating bearish momentum
- The pharmaceutical giant provided FY2026 EPS projections ranging from $14.37 to $14.57 and revealed a strategic collaboration with Alloy Therapeutics focused on antibody discovery
AbbVie (ABBV) experienced a sharp decline of approximately 4.69% during Tuesday’s trading session following regulatory approval granted by the FDA to Johnson & Johnson’s (JNJ) plaque psoriasis medication, Icotyde. Market participants reacted strongly to the news given the critical importance of Skyrizi to AbbVie’s revenue expansion following the Humira patent cliff.
The newly approved Icotyde represents a partnership between J& J and Protagonist Therapeutics (PTGX), offering patients a once-daily oral option for treating plaque psoriasis. This formulation creates a competitive landscape where Skyrizi, AbbVie’s flagship immunology product and major revenue generator, faces a new challenger.
Wall Street researchers maintain confidence in Skyrizi’s market prospects despite the emerging competition. The medication’s clinical performance and administration schedule provide differentiating factors, with forecasts indicating sales growth of 23% reaching into FY2026.
Shares settled near $212.50 following an opening gap down from the previous closing price of $218.60. Intraday price action ranged between $209.42 and $218.60, demonstrating significant downward pressure throughout the session.
Chart Analysis Reveals Downward Momentum
Technically, ABBV has positioned itself below three critical moving averages: the SMA-20 ($227.73), SMA-50 ($224.27), and SMA-200 ($214.95). This alignment across short, intermediate, and long-term averages signals bearish control.
Momentum indicators across multiple timeframes confirm selling pressure. Both daily and weekly RSI measurements register in bearish zones. The CCI and BBP metrics indicate oversold conditions alongside negative price action. Meanwhile, the ADX reveals limited directional strength, and the MACD maintains a neutral stance.
The immediate support zone emerges at $210.83. Should this level fail, additional downside risk increases. Overhead resistance appears at the Ichimoku Kijun line positioned at $227.58.
Traders are monitoring a potential range formation between $210.83 and $215.22, with particular attention to price behavior near the lower boundary for possible mean reversion opportunities.
The 200-day simple moving average at $214.95 may provide temporary support, though the broader technical context continues to favor sellers.
Revenue Transition Challenges and Segment Headwinds
The competitive pressure from Icotyde arrives during a complex period for AbbVie. The organization continues navigating revenue shifts stemming from Humira’s patent expiration, while the aesthetics division — featuring products like Juvederm — experiences persistent sales challenges.
Recent portfolio adjustments by institutional investors reveal reduced ABBV allocations, reflecting evolving perspectives on the stock’s outlook. Insider transaction data shows two selling events across the previous three months, with no corresponding purchase activity.
AbbVie announced a strategic alliance with Alloy Therapeutics targeting the development of enhanced antibody discovery capabilities. The agreement includes initial compensation and performance-based payments, demonstrating ongoing commitment to pipeline advancement.
Management provided FY2026 earnings per share guidance spanning $14.37 to $14.57, signaling confidence in the company’s fundamental business direction.
The Wall Street consensus price target reaches $251.44, accompanied by a recommendation score of 2.2 — indicating moderate bullish sentiment. Institutional investors maintain substantial ownership at 74.71%.
According to GF Value metrics, ABBV registers an estimated fair value of $198.80, suggesting current pricing aligns with intrinsic value assessments.
